Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrated preoperative chemoradiotherapy with bevacizumab for primary and metastatic rectal adenocarcinoma
ACTRN12611000033943Phase 2Active, not recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- May 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, fluorouracil, folinic acid and bevacizumab in rectal adenocarcinoma and rectal cancer, sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Tolerability rate. Started May 2011; status: active, not recruiting.
02
Drugs
oxaliplatinfluorouracilfolinic acidbevacizumab
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on ACTRN12611000033943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000033943.